AZD-1480
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:204510
CAS#:935666-88-9
Description:AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
Price and Availability
AZD-1480 , purity > 98%, isout of stock
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 204510Name: AZD-1480CAS#: 935666-88-9Chemical Formula: C14H14ClFN8Exact Mass: 348.1014Molecular Weight: 348.76596Elemental Analysis:C, 48.21; H, 4.05; Cl, 10.17; F, 5.45; N, 32.13
Synonym:AZD1480; AZD-1480; AZD 1480
IUPAC/Chemical Name:(S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
InChi Key:PDOQBOJDRPLBQU-QMMMGPOBSA-N
InChi Code:InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1
SMILES Code:CC1=CC(NC2=NC(N[C@H](C3=NC=C(F)C=N3)C)=NC=C2Cl)=NN1
Technical Data
Additional Information
AZD1480 inhibits STAT3 in tumor-associated myeloid cells, reducing their number and inhibiting tumor metastasis. Myeloid cell-mediated angiogenesis was also diminished by AZD1480, with additional direct inhibition of endothelial cell function in vitro and in vivo. AZD1480 blocked lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, AZD1480 reduced angiogenesis and metastasis in a human xenograft tumor model. Although the effects of AZD1480 on the tumor microenvironment were important for the observed antiangiogenic activity, constitutive activation of STAT3 in tumor cells themselves could block these antiangiogenic effects, showing the complexity of the JAK/STAT signaling network in tumor progression. Together, AZD1480 can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. (source: Cancer Res. 2011 Nov 1;71(21):6601-10.)
References
1: Liu Y, Holdbrooks AT, De Sarno P, Rowse AL,Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S,Benveniste EN, Qin H. Therapeutic efficacy of suppressing the Jak/STATpathway in multiple models of experimental autoimmune encephalomyelitis.J Immunol. 2014 Jan 1;192(1):59-72. doi: 10.4049/jimmunol.1301513. Epub2013 Dec 9. PubMed PMID: 24323580; PubMed Central PMCID: PMC3934829.
2: Sun ZL, Tang YJ, Wu WG, Xing J, He YF, Xin DM, Yu YL, Yang Y, Han P.AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3cells in vitro. Asian Pac J Cancer Prev. 2013;14(8):4823-7. PubMed PMID:24083752.
3: Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, EllsworthE, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, GomellaL, Huszar D, Nevalainen MT. Pharmacologic inhibition of Jak2-Stat5signaling By Jak2 inhibitor AZD1480 potently suppresses growth of bothprimary and castrate-resistant prostate cancer. Clin Cancer Res. 2013Oct 15;19(20):5658-74. doi: 10.1158/1078-0432.CCR-13-0422. Epub 2013 Aug13. PubMed PMID: 23942095.
4: Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G, EckhardtSG. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.Oncologist. 2013;18(7):819-20. doi: 10.1634/theoncologist.2013-0198.Epub 2013 Jul 11. PubMed PMID: 23847256; PubMed Central PMCID:PMC3720635.
5: Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J,Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E,Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-BonnetG, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. TheIL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.Neoplasia. 2013 Jul;15(7):848-62. PubMed PMID: 23814496; PubMed CentralPMCID: PMC3689247.
6: Yan S, Li Z, Thiele CJ. Inhibition of STAT3 with orally active JAKinhibitor, AZD1480, decreases tumor growth in Neuroblastoma andPediatric Sarcomas In vitro and In vivo. Oncotarget. 2013Mar;4(3):433-45. PubMed PMID: 23531921; PubMed Central PMCID:PMC3717306.
7: Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, BosiA, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMMGruppo Italiano Malattie Mieloproliferative. mTOR inhibitors alone andin combination with JAK2 inhibitors effectively inhibit cells ofmyeloproliferative neoplasms. PLoS One. 2013;8(1):e54826. doi:10.1371/journal.pone.0054826. Epub 2013 Jan 31. PubMed PMID: 23382981;PubMed Central PMCID: PMC3561413.
8: Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, SoaresP. AZD1480 blocks growth and tumorigenesis of RET- activated thyroidcancer cell lines. PLoS One. 2012;7(10):e46869. doi:10.1371/journal.pone.0046869. Epub 2012 Oct 2. PubMed PMID: 23056499;PubMed Central PMCID: PMC3462763.
9: de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W,Heimberger AB. Modulating antiangiogenic resistance by inhibiting thesignal transducer and activator of transcription 3 pathway inglioblastoma. Oncotarget. 2012 Sep;3(9):1036-48. PubMed PMID: 23013619;PubMed Central PMCID: PMC3660053.
10: Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D,Halliday J, Waterton JC, Gore JC, Yankeelov TE. Comparisons of theefficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor(cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI,and histology. Neoplasia. 2012 Jan;14(1):54-64. PubMed PMID: 22355274;PubMed Central PMCID: PMC3281942.
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(ResearchTrianglePark,简称RTP),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中 文美帝药库医药科技公司创立于2008年总部位于美国东海岸
MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务。 MedKoo是世界领先的供应商之一的抗癌化学试剂和激酶抑制剂。我们制造、销售和分发高质量的抗癌小分子肿瘤学研究试剂。我们的使命是建立世界上最全面的抗癌小分子的集合。我们也为医药行业提供高质量的研究服务、医学研究机构和学术机构。我们致力于提供优质的服务和分子有竞争力的价格。MedKoo是您可靠的合作伙伴采购药物发现和药物分子。 MedKoo是世界的抗癌化学试剂和激酶抑制剂供应商之一。我们制造,销售和分销用于肿瘤学研究的高质量抗癌小分子试剂。我们的使命是建立世界上全面的抗癌小分子集合。我们还为制药行业,医学研究组织和学术机构提供高质量的研究服务。我们致力于以具有竞争力的价格提供服务和分子。MedKoo是您可靠的药物发现和药物分子采购合作伙伴。 CRISPR-Cas9是近年兴起的用于靶向基因组特定位置,进行DNA修饰的重要工具。研究发现CRISPR是细菌为了应对病毒的攻击而演化而来的获得性免疫防御机制。具体来说,在CRISPR和Cas9的作用下,经由小RNA分子的引导,靶向并沉默入侵者遗传物质核酸的关键部分。在该系统中,crRNA(CRISPR-derivedRNA)与tracrRNA(trans-activatingRNA)结合形成的复合物能特异性识别靶基因序列,并引导Cas9核酸内切酶在靶定位点剪切双链DNA,随后,细胞的非同源末端连接修复机制(NHEJ)重新连接断裂处的基因组DNA,并引入插入或缺失突变。另外也可以提供一个外源双链供体DNA(Donor)通过同源重组(HR)整合进断裂处的基因组,从而达到对基因组DNA进行修饰的目的。
目前,CRISPR-Cas9系统的高效基因组编辑功能已被应用于多种生物,包括小鼠、大鼠、斑马鱼、秀丽隐杆线虫,也包含多种细菌和植物,甚至在人体上也有应用。
ebiomall.com